Antisense Therapeutics Limited ATHJF OTC

Other OTC • Healthcare • Drug Manufacturers - Specialty & Generic • AU • USD

SharesGrow Score

37/100

0/5 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Antisense Therapeutics Limited (ATHJF) .

Criteria proven by this page:

VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.

Overall SharesGrow Score: 35/100 with 0/7 criteria passed.

SharesGrow 7-Criteria Score

37/100

SG Score

View full scorecard →

—

VALUE

N/A

No coverage

—

FUTURE

N/A

No coverage

✗

PAST

0/100

→ Income

HEALTH

67/100

Debt-to-Equity & liquidity

→ Health

MOAT

50/100

→ Income

GROWTH

58/100

→ Income

✗

INCOME

10/100

→ Income

Valuation Snapshot — ATHJF

Valuation Multiples

P/E (TTM)0.0

Forward P/EN/A

PEG RatioN/A

Forward PEGN/A

P/B Ratio0.00

P/S Ratio3.56

EV/EBITDA0.0

Per Share Data

EPS (TTM)$-0.01

Book Value / Share$0.00

Revenue / Share$0.00

FCF / Share$0.00

Yields & Fair Value

Earnings YieldN/A

Dividend Yield0.00%

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year	EPS (Diluted)	Revenue	Net Income	Net Margin
2015	$0.00	$3.86M	$706.92K	18.3%
2016	$-0.01	$1M	$-2.51M	-251.4%
2017	$-0.02	$69.12K	$-2.75M	-3985.8%
2018	$-0.01	$272.42K	$-2.33M	-855.7%
2019	$-0.01	$586.79K	$-2.94M	-501.8%
2020	$-0.01	$668.43K	$-5.91M	-883.9%
2021	$-0.01	$577.76K	$-8.06M	-1395.1%
2022	$-0.01	$1.78M	$-5.81M	-326.9%
2023	$-0.02	$1.58M	$-11.38M	-720.3%
2024	$-0.01	$2.97M	$-11.92M	-401.6%